How to keep muscle while losing weight on Ozempic or Mounjaro

Roughly a quarter to 40% of the weight you drop on a GLP-1 is lean mass (the fat-free stuff), not fat. Sounds alarming. The detail matters way more than that headline number, so stick with me.

Start with the trials. In the STEP 1 substudy, people took semaglutide 2.4 mg and got scanned with DXA (a body scan that splits you into fat, lean tissue and bone). They lost a lot of fat: total fat mass fell 19.3% and belly fat 27.4% over 68 weeks. Lean mass dropped 9.7%. Do the math and lean mass was close to 40% of all the weight they lost ^[1]. Tirzepatide looked gentler. In the SURMOUNT-1 substudy, fat mass fell 33.9% (about 15.9 kg) and lean mass 10.9% (about 5.6 kg) over 72 weeks. So roughly 74 to 75% of the loss was fat, and 25 to 26% was lean ^[2].

Now the part the scary headlines skip. "Lean" or "fat-free" mass on a DXA scan is not the same thing as muscle. It also counts water, glycogen (your stored carbs), bone and organ tissue. So those lean-loss kilos overstate how much actual muscle you lose. Do not treat the two as equal.

It gets better. Your overall body shape can improve even while raw lean mass drops. In STEP 1, lean mass as a share of total body weight went up 3.0 percentage points, and the lean-to-fat ratio got better (even more so in people who lost at least 15% of their weight) ^[1]. Tirzepatide burned far more fat than lean, so its body-composition shift looked even better.

One last bit of reassurance. In SURMOUNT-1, that 25% lean slice of the weight lost was basically the same in the placebo group ^[2]. In plain terms: GLP-1s are not unusually catabolic (muscle-wasting). Some lean loss rides along with almost any fast weight loss, whether it comes from dieting, surgery or these drugs. What really matters is how much and how fast, especially once you are older. (For the bigger picture on why these drugs matter beyond the scale, see our guide on GLP-1 and longevity.)

Some lean-mass loss is normal, expected, and not automatically a bad thing. The fat you drop buys you real metabolic payoff. What matters for your future is muscle function and strength, not one number on a DXA report.

Why split those hairs? Because strength and mass do not move together in the short term. In the SEMALEAN study, people on semaglutide lost about 3.0 kg of lean mass by month 7, then held steady through month 12. And yet their handgrip strength went up by 4.1 kg, while the share of people with sarcopenic obesity (low muscle plus high fat at the same time) dropped from 49% to 33% ^[8]. They got lighter, lost a little lean tissue on paper, and got stronger. That is exactly the pattern you want.

Now the honest flip side, because pretending it isn't there would be selling you something. In older adults with type 2 diabetes, longer-term semaglutide use has been linked to weaker grip and faster sarcopenia ^[9]. That same work drives home a key point: lean-mass loss does not reliably tell you what strength will do. You cannot read a DXA number and know what happened to your function, in either direction.

So who should be most careful?

• Older adults, whose muscle reserve is already thinner.
• Frail people, or anyone with sarcopenia risk before they even start.
• People losing weight fast, since speed and size of the loss crank up the worry.
• Bone counts too, and rapid loss can hit it, so keep it on the watch list.

The message is not "stay away from these drugs." It is that the scale and the DXA printout cannot tell you whether you are getting frailer or fitter. Strength can. If you are 40-plus, and especially 65-plus, treat strength and function as the real thing to protect, then use the next two sections to actually protect it. (If you are a man over 40, our longevity guide for men 40+ puts muscle in the wider picture.)

Lift weights two to three times a week. That is the single best-proven way to hold onto muscle while you lose weight. Strength training does three things at once: it protects fat-free mass, it tips more of the loss toward fat, and it makes you noticeably stronger.

The headline number comes from a 2025 meta-analysis (a study that pools many trials into one big result) covering 25 randomised trials and 1,608 people ^[4]. It pitted strength training during weight loss against dieting alone, and the picture was clear. The researchers report each result as a standardised effect, which is just a way to compare studies on one scale:

• Fat-free mass: +0.40 (95% CI 0.18 to 0.61), so more muscle kept. (The CI, or confidence interval, is the range the true effect most likely sits in.)
• Fat mass: -0.36 (95% CI -0.49 to -0.23), so more fat lost.
• Strength: +2.36, a big jump in how strong people got.

That is a rare three-for-one: keep more muscle, lose more fat, get stronger, all off the same habit. Studies in older people on calorie-cut diets point the same way: a 2018 meta-analysis ^[10] and a 2017 NEJM trial in dieting older adults with obesity ^[13].

Now the honest catch, because it changes how you read all of this. None of these trials bolted strength training specifically onto semaglutide or tirzepatide. The evidence comes from diet-based and general weight-loss studies. The biology is the same and the advice is sound, but a big GLP-1-specific exercise trial has not reported yet. So treat this as the best available and mechanistically solid, not as proven inside the exact drug setting.

So what do you actually do? Keep it boring and repeatable.

1. Two to three full-body strength sessions a week. That is the dose the data backs, not five.
2. Hit the big movements: a squat or leg press, a push, a pull, a hinge.
3. Add a bit of weight or one more rep when a set starts to feel easy. Progression is the active ingredient.
4. Skip the fancy gym. Bands, dumbbells, or your own bodyweight all count if you make them hard enough.

Walking is great for your heart, but on its own it will not keep your muscle. Here, the lifting is the part that protects you. (Aerobic work still earns its place for your heart and stamina, which is what Zone 2 and VO2max training are for.)

Eat more protein than you used to, especially while the weight is actively coming off. The practical target for older adults and anyone at risk is roughly 1.2 to 1.5 g of protein per kg of body weight per day. In weight-loss practice the aim often sits near the top of that band (around 1.5 g/kg of your target weight).

Where do those numbers come from? Two big consensus papers, both relevant here in DACH: the PROT-AGE position paper ^[5] and the ESPEN expert group ^[6]. They set 1.0 to 1.2 g/kg/day as the baseline for a healthy older adult, then bump it to 1.2 to 1.5 g/kg when someone is ill or at risk. One honest note: these targets were written for aging and general weight loss, then carried over to GLP-1 users. Nobody has tested them head-to-head in semaglutide or tirzepatide trials.

How you eat protein matters as much as how much. The consensus advice is to spread it out. Aim for about 25 to 30 g of good-quality protein per meal across the day, and pair it with your lifting. Protein plus strength training beats either one alone for holding muscle. Higher-protein, energy-restricted diets also help protect fat-free mass while you lose weight ^[14].

Here is the real-world snag nobody warns you about. GLP-1 drugs work by killing your appetite. That is the whole point. But it also makes a protein target genuinely hard to hit, because three small bites in and you feel full. Protein will not happen by accident on these drugs. You have to build meals around it on purpose.

A few moves that work:

• Eat the protein first, before the carbs and veg, while your appetite still plays along.
• Load it earlier in the day, when nausea tends to be milder.
• Keep easy options ready: skyr, quark, eggs, Magerquark, tuna, a protein shake.
• If a full meal feels impossible, a 25 g protein snack still counts toward the daily total.

Think of protein as the food job and lifting as the movement job. Together they are what keep the weight you lose mostly fat.

Track strength and function, not just the number on the scale. The German shorthand says it well: "Funktion vor Waage," function before the scale. A lighter, stronger you is the win, and the bathroom scale cannot tell you which one is happening.

Why not just weigh yourself? Because the scale dumps fat, muscle, water and food into one number. You can lose 8 kg and be fitter, or lose 8 kg and be frailer, and the scale reads the same either way. Strength and function are what tell the two apart.

Good news for DACH readers: the useful tools are cheap and easy to reach.

• Handgrip dynamometry. A simple squeeze test, available in many practices and gyms, that tracks your overall strength surprisingly well. SEMALEAN used exactly this measure ^[8].
• Bioimpedance (BIA). Those body-composition scales you find in many gyms and pharmacies that send a tiny current through you to estimate muscle and fat. Less precise than DXA, but fine for following your own trend over months.
• Chair-stand test. Stand up from a chair and sit back down as many times as you can in 30 seconds, or time five reps. Free, repeatable at home, and a solid stand-in for leg strength and function.

DXA gives the most precise body-composition read, splitting you into fat, lean and bone. The catch in DACH is access and cost: DXA for body composition is harder to get and usually self-pay. A baseline scan plus one follow-up gives you a clean before-and-after, but you do not need it to monitor well.

The trick is to watch the trend over months, not single snapshots. Short-term DXA lean numbers can overstate the real-world harm, since strength often holds or even climbs while lean mass dips, just like SEMALEAN showed ^[8]. And in frail older adults, a reassuring DXA number can understate the longer-term risk ^[9]. So pick one strength test and one function test, retest every couple of months, and trust the direction of the line. If your grip and chair-stand hold steady or improve while the weight drops, you are doing this right.

Yes, a muscle-sparing combo is in the pipeline, and the early data look striking. No, you cannot get it yet. The drug is bimagrumab, an antibody that releases one of the body's brakes on muscle growth (it blocks the activin type II receptor). Researchers tested it alongside semaglutide in the phase 2 BELIEVE trial, with 507 participants.

Here is the result that turned heads. High-dose bimagrumab plus semaglutide produced about 22% weight loss at 72 weeks, and around 92% of that came from fat, with only about 2.9% from lean mass. Semaglutide on its own in the same trial managed about 15.7% weight loss, roughly 75.6% fat and 7.4% lean ^[7]. So the combo lost more weight and held onto far more muscle.

Now ease off the gas. BELIEVE is phase 2 and still investigational. Bimagrumab is not approved, not standard care, and it carries its own side-effect profile that trials are still mapping out. Treat it as a promising future option, not something to ask for next month.

For now, your real-world levers in DACH are still the same three: lifting, protein, monitoring. Which brings us to money, because cost shapes everyone's plan here.

In Germany, Wegovy (semaglutide) and Mounjaro (tirzepatide) for weight loss are not reimbursed. They count as Lifestyle-Arzneimittel under § 34 SGB V, so statutory insurance (GKV) will not pay. You need a Privatrezept and you cover it yourself. Rough 2025/26 self-pay figures:

• Wegovy: about EUR 170 to 270 per month.
• Mounjaro: about EUR 206 to 482 per month, depending on dose.

Only the diabetes uses (say Ozempic, or Mounjaro for type 2 diabetes) might be covered. Austria and Switzerland mirror this same self-pay reality for obesity.

One word of caution on the prices. They depend on dose, they bounce around, and supply has been patchy. These figures come from pharmacy and telehealth price lists, so check a current Lauer-Taxe or pharmacy quote before you budget on any one number.